Skip to main content

Table 2 Patient and tumor characteristics in the neoadjuvant and adjuvant groups from the studies

From: Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases

First authorN NACT/ACTMedian age (year)Clinical stageNuclear gradeHistologyLocal treatment
NACT/ACTNACTACTNACTACTNACTACT
   I/II/IIII/II/III1/2/31/2/3IDC/ILC/OtherIDC/ILC/OtherMB
Clifton132/187< 50, 102/14415/70/020/65/00/4/812/1/7984/0/183/0/2162157
  ≥ 50, 30/43        
Fisher151/234< 50, 82/9610/85/4981/91/112/15/1302/25/200120/7/24190/7/37NRNR
  ≥ 50, 69/138        
Kennedy154/25150/533/80/4389/101/190/14/1355/34/197130/14/10198/28/25207198
Sharma67/7952/58NRNRNRNRNRNRNRNR
Cheng4335/11,148< 50, 1951/3456NR/NR/1517NR/NR/669NANANRNRNRNR
  ≥ 50, 2384/7692        
Yang36/31NANANANRNRNANANRNR
Biswas202/21851/511/105/9669/117/32NANANRNRNANA
Bagegni5621/13,53051.9/55.70/3843/17780/12142/13,8826/649/4530102/1328/11,391NRNRNRNR
Philipovskiy30/7450.4/533/11/1616/41/17NRNR100/0/4a4554
  1. IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, NR not reported, NA not replied, M mastectomy, B breast conserving surgery
  2. aThe data is the sum of neoadjuvant and adjuvant groups